Advances in pharmacotherapy for treating endometriosis

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 16, 2015, Pages 2465-2483

  Tafi, Emanuela ^a,b   Leone Roberti Maggiore, Umberto ^a   Alessandri, Franco ^a   Bogliolo, Stefano ^c   Gardella, Barbara ^c   Vellone, Valerio Gaetano ^b   Grillo, Federica ^b   Mastracci, Luca ^b   Ferrero, Simone ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

aromatase inhibitors; endometriosis; flexible extended combined oral contraceptive; gonadotropin releasing hormone antagonist

Indexed keywords

ANASTROZOLE; CETRORELIX; DANAZOL; DROSPIRENONE; ELAGOLIX; ETHINYLESTRADIOL; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; NAPROXEN; NORETHISTERONE ACETATE; SEQUENTIAL CONTRACEPTIVE AGENT; TRIPTORELIN; ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR; GONADORELIN; HORMONE ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT;

AMENORRHEA; DRUG EFFICACY; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; HORMONAL THERAPY; HUMAN; METRORRHAGIA; PELVIC PAIN; PHARMACEUTICAL CARE; REVIEW; SPOTTING; AGONISTS; ANTAGONISTS AND INHIBITORS; FEMALE;

ANDROSTENES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AROMATASE INHIBITORS; CONTRACEPTIVES, ORAL, COMBINED; ENDOMETRIOSIS; ETHINYL ESTRADIOL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; PROGESTINS;

EID: 84947485987     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1085510     Document Type: Review

References (89)

1. Ferrero S, Arena E, Morando A, Remorgida V. Prevalence of newly diagnosed endometriosis in women attending the general practitioner. Int J Gynaecol Obstet 2010;110:203-7
2. Meuleman C, Vandenabeele B, Fieuws S, et al. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril 2009;92:68-74
3. Morotti M, Remorgida V, Venturini PL, Ferrero S. Endometriosis in menopause: A single institution experience. Arch Gynecol Obstet 2012;286:1571-5
4. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014;29:400-12
5. Ferrero S, Abbamonte LH, Giordano M, et al. Deep dyspareunia and sex life after laparoscopic excision of endometriosis. Hum Reprod 2007;22:1142-8
6. Ford J, English J, Miles WA, Giannopoulos T. Pain, quality of life and complications following the radical resection of rectovaginal endometriosis. BJOG 2004;111:353-6
7. Jacobson TZ, Duffy JM, Barlow D, et al. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2009;4:CD001300
8. Granese R, Perino A, Calagna G, et al. Gonadotropin-releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: A multi-center randomized trial. Acta Obstet Gynecol Scand 2015;94:637-45
9. Somigliana E, Vercellini P, Vigano P, et al. Postoperative medical therapy after surgical treatment of endometriosis: from adjuvant therapy to tertiary prevention. J Minim Invasive Gynecol 2014;21:328-34
10. Quaas AM, Weedin EA, Hansen KR. On-label and off-label drug use in the treatment of endometriosis. Fertil Steril 2015;103:612-25
11. Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010;93:2150-61
12. Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993;60:75-9
13. Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: A placebo-controlled, double-blind, randomized trial. Fertil Steril 2008;90:1583-8
14. Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003;80:560-3
15. Vlahos N, Vlachos A, Triantafyllidou O, et al. Continuous versus cyclic use of oral contraceptives after surgery for symptomatic endometriosis: A prospective cohort study. Fertil Steril 2013;100:1337-42
16. Seracchioli R, Mabrouk M, Frasca C, et al. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: A randomized controlled trial. Fertil Steril 2010;94:464-7
17. Seracchioli R, Mabrouk M, Frasca C, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: A randomized controlled trial. Fertil Steril 2010;93:52-6
18. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16-25
19. Archer DF. Menstrual-cycle-related symptoms: A review of the rationale for continuous use of oral contraceptives. Contraception 2006;74:359-66
20. Ferrero S, Abbamonte LH, Giordano M, et al. What is the desired menstrual frequency of women without menstruation-related symptoms? Contraception 2006;73:537-41
21. Han L, Jensen JT. Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive. Expert Opin Pharmacother 2014;15:2071-9
22. Klipping C, Duijkers I, Fortier MP, et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012;38:73-83
23. Jensen JT, Garie SG, Trummer D, Elliesen J. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an openlabel, three-arm, active-controlled, multicenter study. Contraception 2012;86:110-18
24. Mabrouk M, Solfrini S, Frasca C, et al. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg. Gynecol Endocrinol 2012;28:451-4
25. Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012;38:94-101
26. Ferrero S, Remorgida V, Venturini PL. Current pharmacotherapy for endometriosis. Expert Opin Pharmacother 2010;11:1123-34
27. Brown J, Kives S, Akhtar M. Progestogens and anti-progestogens for pain associated with endometriosis. Cochrane Database Syst Rev 2012;3:CD002122
28. Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: A pilot study. Fertil Steril 2004;81:290-6
29. Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005;84:1375-87
30. Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod 2009;24:3033-41
31. Ferrero S, Camerini G, Ragni N, et al. Letrozole and norethisterone acetate in colorectal endometriosis. Eur J Obstet Gynecol Reprod Biol 2010;150:199-202
32. Muneyyirci-Delale O, Anopa J, Charles C, et al. Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Womens Health 2012;4:149-54
33. Ferrero S, Remorgida V, Venturini PL, Leone Roberti Maggiore U. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: A patient preference study. Eur J Obstet Gynecol Reprod Biol 2014;174:117-22
34. Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review. Am J Obstet Gynecol 2002;187:1101-16
35. Kaser DJ, Missmer SA, Berry KF, Laufer MR. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol 2012;25:105-8
36. Vercellini P, Frattaruolo MP, Somigliana E, et al. Surgical versus lowdose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life. Hum Reprod 2013;28:1221-30
37. Vercellini P, De Giorgi O, Mosconi P, et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002;77:52-61
38. Scala C, Leone Roberti Maggiore U, Remorgida V, et al. Drug safety evaluation of desogestrel. Expert Opin Drug Saf 2013;12:433-44
39. Leone Roberti Maggiore U, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: A prospective open-label comparative study. Acta Obstet Gynecol Scand 2014;93:239-47
40. Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur J Obstet Gynecol Reprod Biol 2014;179:63-8
41. Ferrero S, Pretta S, Bertoldi S, et al. Increased frequency of migraine among women with endometriosis. Human reproduction 2004;19:2927-32
42. Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: A randomized controlled trial. Obstet Gynecol 2012;119:519-26
43. Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrelreleasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 2011;95:492-6
44. Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrelreleasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: A pilot study. Fertil Steril 2003;80:305-9
45. Ferrero S, Tramalloni D, Venturini PL, Remorgida V. Vaginal danazol for women with rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel-releasing intrauterine device. Int J Gynaecol Obstet 2011;113:116-19
46. Bizzarri N, Remorgida V, Leone Roberti Maggiore U, et al. Dienogest in the treatment of endometriosis. Expert Opin Pharmacother 2014;15:1889-902
47. Andres MP, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet 2015. [Epub ahead of print]
48. Morotti M, Sozzi F, Remorgida V, et al. Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. Eur J Obstet Gynecol Reprod Biol 2014;183:188-92
49. Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006;85:314-25
50. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006;21:248-56
51. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005;159:139-44
52. Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009;6:649-75
53. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2007;4:CD000068
54. Johnson NP, Hummelshoj L. World Endometriosis Society Montpellier Consortium Consensus on current management of endometriosis. Hum Reprod 2013;28:1552-68
55. Chwalisz K, Surrey E, Stanczyk FZ. The hormonal profile of NETA: rationale for add-back therapy with gonadotropinreleasing hormone agonists in women with endometriosis. Reprod Sci 2012;19:563-71
56. DiVasta AD, Feldman HA, Sadler Gallagher J, et al. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial. Obstet Gynecol 2015;126(3):617-27
57. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal antiinflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010;1:CD001751
58. Harel Z. Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies. Expert Opin Pharmacother 2012;13:2157-70
59. Küpker W, Felberbaum RE, Krapp M, et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002;5:12-16
60. Weiss JM, Oltmanns K, Gurke EM, et al. Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. Eur J Endocrinol 2001;144:677-85
61. Finas D, Hornung D, Diedrich K, Schultze-Mosgau A. Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother 2006;7:2155-68
62. Bokser L, Srkalovic G, Szepeshazi K, Schally AV. Recovery of pituitarygonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75). Neuroendocrinology 1991;54:136-45
63. Struthers RS, Chen T, Campbell B, et al. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). J Clin Endocrinol Metab 2006;91:3903-7
64. Chen C, Wu D, Guo Z, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropinreleasing hormone receptor. J Med Chem 2008;51:7478-85
65. Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, doubleblind, placebo-controlled study. Reprod Sci 2014;21:363-71
66. Carr B, Dmowski WP, O'Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci 2014;21:1341-51
67. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94:545-51
68. Carr BG L, Dmowski WP, O'Brien C, et al. Elagolix, an oral GnRH antagonist for endometriosis-associated pain: A randomized controlled study. J Endometrios 2013;5:105-15
69. Ferrero S, Remorgida V, Maganza C, et al. Aromatase and endometriosis: estrogens play a role. Ann N Y Acad Sci 2014;1317:17-23
70. Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006;12:49-56
71. Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril 2012;98:1370-9
72. Nawathe A, Patwardhan S, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 2008;115:818-22
73. Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: A systematic review. Reprod Biol Endocrinol 2011;9:89
74. Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: A prospective randomized trial. Hum Reprod 2004;19:160-7
75. Hefler LA, Grimm C, van Trotsenburg M, Nagele F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: A pilot study. Fertil Steril 2005;84:1033-6
76. Remorgida V, Abbamonte HL, Ragni N, et al. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril 2007;88:724-6
77. Remorgida V, Abbamonte LH, Ragni N, et al. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust N Z J Obstet Gynaecol 2007;47:222-5
78. Roghaei MA, Tehrany HG, Taherian A, Kolein N. Effects of Letrozole Compared with Danazol on Patients with Confirmed Endometriosis: A Randomized Clinical Trial. IJFS 2010;4:67-72
79. Alborzi S, Hamedi B, Omidvar A, et al. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet 2011;284:105-10
80. Ferrero S, Venturini PL, Gillott DJ, Remorgida V. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: A randomized controlled trial. Reprod Biol Endocrinol 2011;9:88
81. Takayama K, Zeitoun K, Gunby RT, et al. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998;69:709-13
82. Ferrero S, Leone Roberti Maggiore U, Scala C, et al. Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies. Arch Gynecol Obstet 2013;287:447-53
83. Lall Seal S, Kamilya G, Mukherji J, et al. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review. Fertil Steril 2011;95:291
84. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007;43:2523-31
85. Lindsay SF, Luciano DE, Luciano AA. Emerging therapy for endometriosis. Expert Opin Emerg Drugs 2015; Epub ahead of print
86. (ID protocol number: NCT01931670). Available from: http://www.clinicaltrials. gov/[Last accessed 9 June 2015]
87. Ferrero S, Venturini PL, Ragni N, et al. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs 2009;69:943-52
88. Razzi S, Fava A, Sartini A, et al. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG 2004;111:182-4
89. Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: A novel treatment for endometriosis. Fertil Steril 2005;84:300-4